MENU

Fox Chase Cancer Center News

April 4, 2022

Fox Chase Researchers Find Higher Levels of Estrogen Derivatives in Lung Cancer Patients Who Have Never Smoked

PHILADELPHIA (April 4, 2022)—Nonsmokers with the two most common types of driver-gene mutated lung cancer have higher levels of the estrogen derivative 4-OHE, according to early data from researchers at Fox Chase Cancer Center, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 8-13, 2022.

April 4, 2022

Fox Chase Molecular Therapeutics Researchers to Present Findings From Recent Studies at AACR Annual Meeting

PHILADELPHIA (April 4, 2022)— During the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 8-13, 2022, researchers from the lab of Philip Abbosh, MD, PhD, an assistant professor in the Molecular Therapeutics research program at Fox Chase Cancer Center, will present findings from recent studies.

April 4, 2022

Dr. Elizabeth Plimack Appointed Deputy Director at Fox Chase Cancer Center

PHILADELPHIA (April 4, 2022)—Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Deputy Director.

March 31, 2022

Newly Defined Renal Neoplasm Has Low Risk of Metastasis, So Patients May Be Able to Avoid Surgery

PHILADELPHIA (March 31, 2022)—Researchers at Fox Chase Cancer Center have published a new study that identifies several characteristics of papillary renal neoplasm with reverse polarity (PRNRP), a neoplasm that may simply be monitored rather than removing it through surgery.

March 30, 2022

Fox Chase Researchers Study Role of PP2A/B55α in Cellular Processes and Cancer Development

PHILADELPHIA (March 30, 2022)—In a recent study, researchers from Fox Chase Cancer Center have begun to define how PP2A/B55α recognizes its substrates, which are protein targets. The work may ultimately help the researchers identify other targets involved in cancer progression.

March 25, 2022

Fox Chase Researchers Study PTEN Mutations in Colorectal Cancer Patients to Enhance Clinical Targeting

PHILADELPHIA (March 25, 2022)—In a new study released today in the prestigious journal Nature Communications, researchers at Fox Chase Cancer Center who looked at over 34,000 colorectal cancer patients learned that certain PTEN mutations occur in distinct patterns in specific subsets of colorectal cancer. The finding could help clinicians administer available therapies to colorectal cancer patients in a more personalized way.

March 16, 2022

Researchers Identify Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma

PHILADELPHIA (March 16, 2022)—Researchers from Fox Chase Cancer Center have published an analysis of strategies for treating retroperitoneal soft tissue sarcoma (RPS), a form of cancer that has historically been understudied due to its rarity.

March 15, 2022

Camille Ragin Named Associate Director of Diversity, Equity, and Inclusion at Fox Chase Cancer Center

PHILADELPHIA (March 15, 2022)—Fox Chase Cancer Center has announced the appointment of Camille Ragin, PhD, MPH, as Associate Director of Diversity, Equity, and Inclusion (DEI).

Pages

Connect with Fox Chase